{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:59:52Z","timestamp":1791500392590,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4816,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.exphem.2008.12.008","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T07:52:09Z","timestamp":1237449129000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effects of imatinib mesylate in osteoblastogenesis"],"prefix":"10.1016","volume":"37","author":[{"given":"Daniele","family":"Tibullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesarina","family":"Giallongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.12.008_bib1","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.12.008_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2008.12.008_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1634\/stemcells.22-3-377","article-title":"Mesenchymal stem cells can be differentiated into endothelial cells in vitro","volume":"22","author":"Oswald","year":"2004","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2008.12.008_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2008.12.008_bib5","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0959-8049(02)00836-5","volume":"39","author":"Verweij","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2008.12.008_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.exphem.2008.12.008_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jbmr.5650110305","article-title":"Isolation and characterization of osteoblast precursor cells from human bone marrow","volume":"11","author":"Rickard","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.exphem.2008.12.008_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1634\/stemcells.19-3-180","article-title":"Bone marrow stromal stem cells: nature, biology, and potential applications","volume":"19","author":"Bianco","year":"2001","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2008.12.008_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v17.i2.10","article-title":"Molecular signaling in bone regeneration","volume":"17","author":"Bahar","year":"2007","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.exphem.2008.12.008_bib10","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1210\/endo.137.9.8756585","article-title":"The human osteoclast precursor circulates in the monocyte fraction","volume":"137","author":"Fujikawa","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.exphem.2008.12.008_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2008.12.008_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2008.12.008_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2008.12.008_bib14","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.12.008_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.exphem.2008.12.008_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1016\/j.exphem.2008.12.008_bib17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.12.008_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"Jonsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.12.008_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2008.12.008_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.imlet.2006.02.002","article-title":"A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation","volume":"105","author":"Lee","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1016\/j.exphem.2008.12.008_bib21","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.exphem.2008.12.008_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.leukres.2007.07.020","article-title":"Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines","volume":"32","author":"Wihlidal","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2008.12.008_bib23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.exphem.2008.12.008_bib24","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.1074\/jbc.M705578200","article-title":"Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal","volume":"283","author":"Javed","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.12.008_bib25","doi-asserted-by":"crossref","first-page":"40515","DOI":"10.1074\/jbc.M604508200","article-title":"BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network","volume":"281","author":"Hassan","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.12.008_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0092-8674(00)80257-3","article-title":"Osf2\/Cbfa1: a transcriptional activator of osteoblast differentiation","volume":"89","author":"Ducy","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2008.12.008_bib27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F","article-title":"Cbfa1 isoform overexpression upregulates osteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells","volume":"74","author":"Xiao","year":"1999","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.exphem.2008.12.008_bib28","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","author":"Gaur","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.12.008_bib29","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1128\/MCB.20.23.8783-8792.2000","article-title":"Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12","volume":"20","author":"Lee","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.exphem.2008.12.008_bib30","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/j.1742-4658.2007.05840.x","article-title":"Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes","volume":"274","author":"Herpin","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.exphem.2008.12.008_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1359\/jbmr.060109","article-title":"BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype","volume":"21","author":"Phimphilai","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.exphem.2008.12.008_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/39348","article-title":"Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1","volume":"389","author":"Kretzschmar","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2008.12.008_bib33","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1101\/gad.1202604","article-title":"In vivo convergence of BMP and MAPK signaling pathways: impact of differential Smad1 phosphorylation on development and homeostasis","volume":"18","author":"Aubin","year":"2004","journal-title":"Genes Dev"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:09Z","timestamp":1759566429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X09000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0301472X09000071"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.12.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of imatinib mesylate in osteoblastogenesis","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}